These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31712584)

  • 1. Modulation of brain activation during executive functioning in autism with citalopram.
    Wichers RH; Findon JL; Jelsma A; Giampietro V; Stoencheva V; Robertson DM; Murphy CM; McAlonan G; Ecker C; Rubia K; Murphy DGM; Daly EM
    Transl Psychiatry; 2019 Nov; 9(1):286. PubMed ID: 31712584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine.
    Wichers RH; Findon JL; Jelsma A; Giampietro V; Stoencheva V; Robertson DM; Murphy CM; Blainey S; McAlonan G; Ecker C; Rubia K; Murphy DGM; Daly EM
    Mol Autism; 2021 Feb; 12(1):14. PubMed ID: 33608048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.
    Windischberger C; Lanzenberger R; Holik A; Spindelegger C; Stein P; Moser U; Gerstl F; Fink M; Moser E; Kasper S
    Neuroimage; 2010 Jan; 49(2):1161-70. PubMed ID: 19833214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin differentially modulates the temporal dynamics of the limbic response to facial emotions in male adults with and without autism spectrum disorder (ASD): a randomised placebo-controlled single-dose crossover trial.
    Wong NML; Findon JL; Wichers RH; Giampietro V; Stoencheva V; Murphy CM; Blainey S; Ecker C; Murphy DG; McAlonan GM; Daly E
    Neuropsychopharmacology; 2020 Dec; 45(13):2248-2256. PubMed ID: 32388538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of acute serotonin challenge on executive planning in patients with obsessive-compulsive disorder (OCD), their first-degree relatives, and healthy controls.
    Lochner C; Chamberlain SR; Kidd M; Taljaard L; Fineberg NA; Robbins TW; Stein DJ
    Psychopharmacology (Berl); 2020 Oct; 237(10):3117-3123. PubMed ID: 32638035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial.
    Wong NM; Dipasquale O; Turkheimer F; Findon JL; Wichers RH; Dimitrov M; Murphy CM; Stoencheva V; Robertson DM; Murphy DG; Daly E; McAlonan GM
    J Psychopharmacol; 2022 Jun; 36(6):723-731. PubMed ID: 35491679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disorder-dissociated effects of fluoxetine on brain function of working memory in attention deficit hyperactivity disorder and autism spectrum disorder.
    Chantiluke K; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
    Psychol Med; 2015 Apr; 45(6):1195-205. PubMed ID: 25292351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontoparietal Network in Executive Functioning in Autism Spectrum Disorder.
    May KE; Kana RK
    Autism Res; 2020 Oct; 13(10):1762-1777. PubMed ID: 33016005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors.
    Simonoff E; Mowlem F; Pearson O; Anagnostou E; Donnelly C; Hollander E; King BH; McCracken JT; Scahill L; Sikich L; Pickles A
    J Child Adolesc Psychopharmacol; 2022 May; 32(4):233-241. PubMed ID: 35501967
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving response inhibition systems in frontotemporal dementia with citalopram.
    Hughes LE; Rittman T; Regenthal R; Robbins TW; Rowe JB
    Brain; 2015 Jul; 138(Pt 7):1961-75. PubMed ID: 26001387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered perspective-dependent brain activation while viewing hands and associated imitation difficulties in individuals with autism spectrum disorder.
    Okamoto Y; Kitada R; Miyahara M; Kochiyama T; Naruse H; Sadato N; Okazawa H; Kosaka H
    Neuroimage Clin; 2018; 19():384-395. PubMed ID: 30035023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.
    Ye Z; Altena E; Nombela C; Housden CR; Maxwell H; Rittman T; Huddleston C; Rae CL; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Brain; 2014 Apr; 137(Pt 4):1145-55. PubMed ID: 24578545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
    Williams K; Brignell A; Randall M; Silove N; Hazell P
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004677. PubMed ID: 23959778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
    Najjar F; Owley T; Mosconi MW; Jacob S; Hur K; Guter SJ; Sweeney JA; Gibbons RD; Cook EH; Bishop JR
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):467-74. PubMed ID: 26262902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
    Williams K; Wheeler DM; Silove N; Hazell P
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004677. PubMed ID: 20687077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal functional activation and maturation of ventromedial prefrontal cortex and cerebellum during temporal discounting in autism spectrum disorder.
    Murphy CM; Christakou A; Giampietro V; Brammer M; Daly EM; Ecker C; Johnston P; Spain D; Robertson DM; ; Murphy DG; Rubia K
    Hum Brain Mapp; 2017 Nov; 38(11):5343-5355. PubMed ID: 28744969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatiotemporal brain activation pattern following acute citalopram challenge is dose dependent and associated with neuroticism: A human phMRI study.
    Edes AE; McKie S; Szabo E; Kokonyei G; Pap D; Zsombok T; Hullam G; Gonda X; Kozak LR; McFarquhar M; Anderson IM; Deakin JFW; Bagdy G; Juhasz G
    Neuropharmacology; 2020 Jun; 170():107807. PubMed ID: 31593709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
    Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
    J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram attenuates social behavior deficits in the BTBR T
    Cai Y; Wang L; Nalvarte I; Xiao R; Li X; Fan X
    Brain Res Bull; 2019 Aug; 150():75-85. PubMed ID: 31047973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociable and common effects of methylphenidate, atomoxetine and citalopram on response inhibition neural networks.
    Nandam LS; Hester R; Bellgrove MA
    Neuropsychologia; 2014 Apr; 56():263-70. PubMed ID: 24513025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.